We recently announced the Fifth Generation of Concentriq. This generation helps pathologists spend their time on high-judgment interpretation, and scientists move from an early signal to a confident program decision, faster. It does this by building clinically and scientifically grounded intelligence into the workflows experts already use across drug discovery, development, and case review. Our announcement covered what we built and why we built it. This post is about the how. 

AI won't replace pathologists. But it will redefine what they do. Proscia CEO David West challenges the "replacement" narrative around AI in medicine — and makes the case that the real opportunity is using AI to eliminate administrative burden, not diagnostic expertise.

Precision medicine companies are processing unprecedented molecular volumes, serving distributed health system networks, and racing to deploy AI-driven diagnostics that can meaningfully improve patient outcomes. An enterprise pathology AI platform can transform fragmented workflows into a scalable, AI-ready engine for precision medicine growth.

Proscia has been named Global 2026 Best in KLAS for Digital Pathology in Europe and earned the top performance score in the U.S. in the 2026 KLAS Digital Pathology Report. Here’s why life sciences organizations should take notice.

Learn why Epic Beaker integration is now a strategic requirement (not a technical nice-to-have), what “Epic-native” digital pathology truly means in practice, and how leading AMCs are approaching integration to reduce risk, accelerate value, and prepare for AI-driven diagnostics.

The evolution of digital pathology, or whole slide imaging (WSI), has taken over 20 years. As AI-enabled digital pathology continue to advance, it will likely follow most technology curves; the costs will continue to come down and the variety of applications will increase.

Built on a new AI-native architecture, Concentriq delivers clinically and scientifically grounded intelligence to decisions throughout drug discovery, development, and case review.

By adopting the Concentriq® platform, NextGen Pathology will lay an AI foundation for advancing its subspecialty services and positioning itself as a strategic partner for biopharmaceutical research.

Following Proscia’s Global Best in KLAS win in Europe, Concentriq is now the highest-rated digital pathology platform across multiple regions

Diagnostic labs and drug development programs are under more pressure than ever — and a pathology platform with AI bolted on can't keep up. See the first official demo of Concentriq Fifth Generation, built with an enterprise AI layer at its core. Hear directly from customers optimizing clinical diagnostic workflows and advancing drug development research.

See how the platform works in practice across academic medical centers, health systems, and reference labs. Guest speaker Daniel Roberts, MD, Medical Director of Digital Pathology at Cleveland Clinic, shares what digital pathology adoption and change management actually looks like at one of the nation's largest academic medical centers.

AWS and Proscia Enterprise Digital Pathology Data Management‍: How Leading AP Labs Scale Digitization While Controlling Costs and Building an AI-Ready Foundation

See how the latest Concentriq LS releases provide the performance, precision, and interoperability that every life sciences lab needs to succeed in a data-intensive drug development research environment.

Discover how to build a clear project vision, prepare your workflows for LIS integration, and empower pathologist champions to guide the transition to digital with ECPC, LigoLab and Proscia.